An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.

Category Primary study
Registry of TrialsClinical Trials Information System
Year 2024
This article has no abstract
Epistemonikos ID: d80e317a46e66d7273612e54b4e4c655797f9874
First added on: Mar 21, 2025